Here’s what you need to know:
1. The risk assessment tool stratifies patients into risk categories based on susceptibility to single-nucleotide polymorphisms.
2. A goal of the risk assessment tool is to identify people at high and low risk for colorectal cancer, to assist patients when deciding what age and frequency they should begin screening.
3. Genetic Technologies, a molecular diagnostics company, is responsible for the commercial development of the test. The company has already developed a risk assessment test for sporadic breast cancer, called BREVAGenplus, which uses a similar technology.
4. University of Melbourne will leverage its expertise in single-nucleotide polymorphism and DNA sequencing to partner with Genetic Technologies in ongoing research related to this risk assessment tool.
More articles on gastroenterology and endoscopy:
Outreach to cirrhosis patients increases likelihood of liver cancer screening: 3 study insights
Dr. Fabio Cominelli to study inflammatory bowel disease with XBiotech: 3 things to know
Allergan taps paratriathlete Amy Dixon as spokesperson for IBS
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
